Marketed
Products:
Samaritan has collaborative relationships with other pharmaceutical
companies to commercialize branded approved prescription products
in selected niche territories, such as, in Greece, Albania,
Bosnia, Bulgaria, Croatia, Cyprus, Czech Republic, Egypt,
FYROM, Hungary, Montenegro, Poland, Romania, Serbia, Slovakia,
Slovania, Syria and Turkey. We use our expertise to register
approved drugs with regulatory agencies in the country we
have acquired the rights for; and then, upon regulatory approval,
we distribute, market and sell these products. Our efforts are focused on speciatlist
physicians in private practice or at hospitals and major medical
centers in our territories. Below is a description of our
in-licensed products.
|
| NARCOTIC
ANALGESICS
(PAIN RELIEF MEDICATIONS) |
TERRITIORIES
|
PRODUCT
DESCRIPTION AND DOSAGE |
| ORAMORPH®
(morphine sulphate)
Oral Solution

 |
|
ORAMORPH®
(Orr-a-morf) is
morphine sulphate in an oral solution and is used for managing moderate
to severe chronic pain for more than a few days. It works by dulling the
pain perception center in the brain. Oramorph® is approved by the Italian
Ministry of Health (The equivalent to the US FDA) and is marketed by Molteni
in Italy. Oramorph®
is approved by the Italian Ministry of Health (The equivalent to the US
FDA) and is owned by Molteni Farmaceutici, Inc. and marketed by Molteni
Farmaceutici, Inc. in Italy.
On January 1, 2007,
Samaritan entered into an exclusive licensing agreement with Molteni Farmaceutici
for the marketing and distribution of Oramorph® in the countries of Greece
and Cyprus.
Currently, Oramorph
has a Greek marketing authorization. Oramorph can only be sold in Greece
via a centralized government tender. Samaritan is preparing a tender application
for the next request by Greek authorities for applications. |
|
|
MORPHINE SULPHATE®
(morphine sulphate)
Injectable Form


|
|
MORPHINE
SULPHATE ®
(mor-fene sul-fate) relieves moderate to severe pain by binding to brain
receptors. Morphine Sulphate may be used to control the pain following surgery,
child birth, and other procedures. It may also be used to treat the pain
associated with cancer, heart attacks, sickle cell disease and other medical
conditions.
On January 1, 2007,
Samaritan entered into an exclusive licensing agreement with Molteni Farmaceutici
for the marketing and distribution of Morphine
Sulphate®
in the countries of Greece and Cyprus. Samaritan has received its first
tender purchase order of Morphine Sulfate and Pethidine from the Institute
of Pharmaceutical Research and Technology (IFET).
Currently, Morphine
Sulphate® can only be sold in Greece and Cyprus via a centralized government
tender. Samaritan is preparing a tender application for the next request
by Greek authorities for applications.
|
|
|
PETHIDINE®
(peth-i-dine)
Injectable Form

|
|
PETHIDINE
® (peth-i-dine)
indicated for the treatment of moderate to severe pain, and may be prescribed
as a preoperative medication, support of anesthesia, and obstetric analgesia.
Samaritan has
received its first tender purchase order of Morphine Sulfate and Pethidine
from the Institute of Pharmaceutical Research and Technology (IFET).
Currently, Pethidine®
can only be sold in Greece and Cyprus via a centralized government tender.
Samaritan is preparing a tender application for the next request by Greek
authorities for applications.
|
|
| RAPYDAN®
(lidocaine 70 mg and tetracaine 70 mg)
Topical
Anesthetic Patch

 |
|
RAPYDAN®
(Rap-e-dan)
Rapydan® is indicated for local dermal analgesia on intact skin, and consists
of a thin, uniform, local anesthetic formulation with an integrated, oxygen-activated
heating component that is intended to enhance the delivery of the local
anesthetic. The drug formulation is an eutectic mixture of lidocaine 70
mg and tetracaine 70 mg. Rapydan® is indicated to provide local dermal
analgesia for superficial venous access and superficial dermatological
procedures such as excision, electrodessication and shave biopsy of skin
lesions.
On August 3, 2007,
Samaritan signed an exclusive agreement with EUSA for the marketing and
distribution of the product RAPYDAN® in Greece and Cyprus. Rapydan®
is an approved FDA prescription product under the name SYNERA® and
is owned by ZARS Pharmaceuticals, Inc. and marketed by Endo Pharmaceuticals,
Inc. in the US.
Currently, Samaritan
Pharmaceuticals is utilizing the US FDA approved regulatory file in preparing
marketing applications for Rapydan® with regulatory authorities in
Greece and Cyprus to gain country marketing authorization drug approval. |
| DRUG
ADDICTION THERAPY |
TERRITIORIES
|
PRODUCT
DESCRIPTION AND DOSAGE |
| METHADONE
HCL®
(methadone hydrochloride)
Oral Solution Presentations

|
|
METHADONE
HCL® (meth-a-done)
is an opiate agonist. Methadone
HCL® prevents
heroin or morphine from interacting with receptors for natural painkillers
called endorphins, blocking the effects of the addictive drugs and reducing
the physical cravings. Methadone
HCL® is
approved by the Italian Ministry of Health (The equivalent to the US FDA)
and is owned by Molteni Pharmaceuticals, Inc. and marketed by Molteni Farmaceutici,
Inc. in Italy.
On January 1, 2007,
Samaritan entered into an exclusive licensing agreement with Molteni Farmaceutici
for the marketing and distribution of Methadone
HCL®
in the countries of Greece and Cyprus.
Currently, Methadone
HCL® can only be sold in Greece and Cyprus via a centralized government
tender. Samaritan is preparing a tender application for the next request
by Greek authorities for applications.
|
|
| NALOXONE
MOLTENI®
(naloxone hydrochloride)
Injectable Form

|
|
NALOXONE
MOLTENI ® (nal-ox-own) is
an opioid antagonist which reverses the effects of opioid overdose, for
example heroin and morphine overdose. Specifically, Naloxone is used in
opioid overdoses for countering life-threatening depression of the central
nervous system and respiratory system. On
January 1, 2007, Samaritan entered into an exclusive licensing agreement
with Molteni Farmaceutici for the marketing and distribution of Naloxone
Molteni ® in the countries of Greece and Cyprus.
Currently, Naloxone
Molteni® will be sold and distributed by Samaritan on a named patient
basis until the pricing and the reimbursement of Naloxone Molteni® is
established in Greece and Cyprus, with the relevant regulatory authorities.
|
|
| NALTREXONE
HCL®
(naltrexone hydrochloride)
Oral Tablet Form

|
|
NALTREXONE®
(nal-trex-own) is
an opioid antagonist which is used to help people who have a narcotic or
alcohol addiction stay drug free. Naltrexone HCL® is used after the patient
has stopped taking drugs or alcohol. It works by blocking the effects of
narcotics or by decreasing the craving for alcohol. Naltrexone
HCL® is approved by the Italian Ministry of Health (The equivalent to
the US FDA) and is owned by Molteni Farmaceutici, Inc. and marketed by
Molteni Farmaceutici, Inc. in Italy.
On January 1, 2007,
Samaritan entered into an exclusive licensing agreement with Molteni Farmaceutici
for the marketing and distribution of Naltrexone HCL® in the countries
of Greece and Cyprus.
Currently, Samaritan
Pharmaceuticals is utilizing the Italian Ministry of Health approved regulatory
file in preparing marketing applications for Naltrexone HCL® with regulatory
authorities in Greece and Cyprus to gain country marketing authorization
drug approval. |
| ANESTHESIA |
TERRITIORIES |
PRODUCT
DESCRIPTION AND DOSAGE |
| MEPIVAMOL®
(Mepivacaine)
Injectable
Form

|
|
MEPIVAMOL®
(Me-piv-a-mol) is an effective and reliable local anesthetic of intermediate
duration and low systemic toxicity. It is widely used for regional anesthetic
procedures such as IVRA, infiltration, epidural blockade, plexus and peripheral
nerve blockade. Mepivamol® is approved by the Italian Ministry of Health
(The equivalent to the US FDA) and is owned by Molteni Farmaceutici, Inc.
and marketed by Molteni Farmaceutici, Inc. in Italy.
On January 1, 2007, Samaritan entered into an exclusive
licensing agreement with Molteni Farmaceutici for the marketing and distribution
of Mepivamol®
in the countries of Greece and Cyprus. Currently, Samaritan Pharmaceuticals
is utilizing the Italian Ministry of Health approved regulatory file in
preparing marketing applications for Mepivamol®
with regulatory authorities in Greece and Cyprus to gain country marketing
authorization drug approval.
|
|
|
More products coming soon... |
|
|
|